Neumora Therapeutics Upgraded to Outperform by RBC Capital Markets.

lunes, 1 de diciembre de 2025, 2:36 pm ET1 min de lectura
NMRA--

Neumora Therapeutics has been upgraded to outperform from sector perform by RBC Capital Markets, citing its pipeline beyond neurology not being reflected in its stock price. The firm increased its price target to $7 from $4, representing a 213% upside based on the Nov. 28 close.

Neumora Therapeutics Upgraded to Outperform by RBC Capital Markets.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios